title: Gatifloxacin treatment for chronic prostatitis: a prospective multicenter clinical trial.
abstract: Antimicrobial treatment is usually used for chronic prostatitis. However, the efficacy of such treatment has not been fully evaluated. We conducted a study to evaluate the efficacy of gatifloxacin for patients with chronic prostatitis using the Japanese version of the National Institutes of Health Chronic Prostatitis Symptom Index (JPN-NIH CPSI). The study included 46 patients for final analysis. Patients who were younger than 65 years of age were treated with 200 mg gatifloxacin twice daily, and those who were 65 years and older were treated with 100 mg gatifloxacin twice daily, for 4-8 weeks. The study consisted of 10 patients in category II, 13 in category IIIA, 11 in category IIIB, and 12 who were unclassified. The gatifloxacin treatment resulted in significant reductions in the scores on the JPN-NIH CPSI. Of the total number of patients, 58.1% and 27.9% were 25% and 50% responders, respectively, 4 weeks after treatment, and these figures improved to 66.7% and 33.3%, respectively, 8 weeks after treatment. No significant difference was found in the changes in symptom scores between Category II and Category IIIA/IIIB groups. In conclusion, gatifloxacin treatment improved the symptoms in patients with chronic bacterial and nonbacterial prostatitis. This study is the first in this country to evaluate the efficacy of antimicrobial treatment for chronic prostatitis by using the NIH CPSI.
authors.affiliation: Department of Urology, Sapporo Medical University School of Medicine, S-1, W-16, Sapporo, 060-8543, Japan. Kunishim@sapmed.ac.jp
authors.forename: Yasuharu
authors.initials: Y
authors.lastname: Kunishima
authors.forename: Koh
authors.initials: K
authors.lastname: Takeyama
authors.forename: Satoshi
authors.initials: S
authors.lastname: Takahashi
authors.forename: Masanori
authors.initials: M
authors.lastname: Matsukawa
authors.forename: Mikio
authors.initials: M
authors.lastname: Koroku
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Tanda
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Tanaka
authors.forename: Takaoki
authors.initials: T
authors.lastname: Hirose
authors.forename: Akihiko
authors.initials: A
authors.lastname: Iwasawa
authors.forename: Masahiro
authors.initials: M
authors.lastname: Nishimura
authors.forename: Kou-ichi
authors.initials: K
authors.lastname: Takeda
authors.forename: Nobukazu
authors.initials: N
authors.lastname: Suzuki
authors.forename: Hiroki
authors.initials: H
authors.lastname: Horita
authors.forename: Akifumi
authors.initials: A
authors.lastname: Yokoo
authors.forename: Taiji
authors.initials: T
authors.lastname: Tsukamoto
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D024841:Fluoroquinolones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000077734:Gatifloxacin; D006801:Humans; D008297:Male; D008875:Middle Aged; D009316:National Institutes of Health (U.S.) / Q000592:standards; D011472:Prostatitis / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014481:United States
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D000077734:Gatifloxacin